BioSpace News Archive

MOASC will also be partnering with The American Journal of Managed Care®

Thousands Participate in the Nineteenth Annual Walk at Jones Beach State Park

Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard

FEP Blue Focus(SM) moves into second year with no premium increase, while Standard and Basic Options introduce programs to help members live healthier lives

NetNoggin® analyzes big data to better understand why Alzheimer’s drugs fail clinical trials and how the Alzheimer’s community reacts to the failures.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to purchase an aggregate of 43,600 shares of Akebia’s common stock on September 30, 2019, as inducements material to each such employee’s entering into employment with Akebia.

Arrowhead Pharmaceuticals Inc. announced that it will host a Research & Development Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule platform from 8:30 a.m. to 11:30 a.m. EDT on October 18, 2019, in New York City.

Results on November 5, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.

The TGA is considered one of the most stringent regulatory agencies in the world and TGA certification represents meeting the agency’s high standards for manufacturing therapeutic goods, including nutritional supplements.

Availity, the nation’s largest real-time health information network, named Frank J. Manzella its new Senior Vice President of Corporate Development & Strategy.